Enterprise Value
2.532B
Cash
337.5M
Avg Qtr Burn
N/A
Short % of Float
0.00%
Insider Ownership
14.68%
Institutional Own.
69.29%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KIMMTRAK (Tebentafusp) (gp100) Details Metastatic uveal melanoma, Cancer, Melanoma | Approved Quarterly sales | |
KIMMTRAK (Tebentafusp) +/- anti-PD1 Details Cancer, Melanoma | Phase 2/3 Data readout | |
GSK01 (NY-ESO-1) Details Cancer, Synovialsarcoma | Phase 1 Data readout | |
IMC-M113V Details Viral infection, Human immunodeficiency virus | Phase 1 Data readout | |
IMC-C103C (MAGE-A4) Details Ovarian cancer, Solid tumor/s, Head and neck cancer, Non-small cell lung carcinoma, Cancer, Gastric cancer | Phase 1 Data readout | |
IMC-F106C (PRAME) Details Ovarian cancer, Solid tumor/s, Cancer, Breast cancer, Endometrial cancer | Phase 1 Data readout |